SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
Europe - FRA:SRT3 - DE0007165631
238.2 EUR
+1.9 (+0.8%)
Taking everything into account, SRT3 scores 3 out of 10 in our fundamental rating. SRT3 was compared to 20 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of SRT3 have multiple concerns. SRT3 is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRT3 was profitable.
SRT3 had a positive operating cash flow in the past year.
SRT3 had positive earnings in each of the past 5 years.
Each year in the past 5 years SRT3 had a positive operating cash flow.
1.2 Ratios
SRT3 has a Return On Assets of 1.39%. This is in the lower half of the industry: SRT3 underperforms 75.00% of its industry peers.
Looking at the Return On Equity, with a value of 5.01%, SRT3 is doing worse than 70.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.71%, SRT3 is doing worse than 75.00% of the companies in the same industry.
SRT3 had an Average Return On Invested Capital over the past 3 years of 8.34%. This is in line with the industry average of 7.43%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.39% | ||
| ROE | 5.01% | ||
| ROIC | 4.71% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
SRT3 has a worse Profit Margin (3.80%) than 75.00% of its industry peers.
In the last couple of years the Profit Margin of SRT3 has declined.
The Operating Margin of SRT3 (14.06%) is worse than 60.00% of its industry peers.
In the last couple of years the Operating Margin of SRT3 has declined.
SRT3's Gross Margin of 46.48% is fine compared to the rest of the industry. SRT3 outperforms 70.00% of its industry peers.
In the last couple of years the Gross Margin of SRT3 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.06% | ||
| PM (TTM) | 3.8% | ||
| GM | 46.48% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
SRT3 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, SRT3 has more shares outstanding
SRT3 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SRT3 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.40 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.40, SRT3 perfoms like the industry average, outperforming 45.00% of the companies in the same industry.
SRT3 has a debt to FCF ratio of 8.92. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.92 years to pay back of all of its debts.
SRT3 has a Debt to FCF ratio of 8.92. This is in the lower half of the industry: SRT3 underperforms 60.00% of its industry peers.
A Debt/Equity ratio of 1.28 is on the high side and indicates that SRT3 has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.28, SRT3 is doing worse than 85.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.28 | ||
| Debt/FCF | 8.92 | ||
| Altman-Z | 2.4 |
ROIC/WACC0.62
WACC7.64%
2.3 Liquidity
A Current Ratio of 0.95 indicates that SRT3 may have some problems paying its short term obligations.
SRT3's Current ratio of 0.95 is on the low side compared to the rest of the industry. SRT3 is outperformed by 85.00% of its industry peers.
SRT3 has a Quick Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.49, SRT3 is doing worse than 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 59.34% over the past year.
The earnings per share for SRT3 have been decreasing by -11.87% on average. This is quite bad
SRT3 shows a small growth in Revenue. In the last year, the Revenue has grown by 5.82%.
Measured over the past years, SRT3 shows a quite strong growth in Revenue. The Revenue has been growing by 13.10% on average per year.
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.23%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.54%
3.2 Future
Based on estimates for the next years, SRT3 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.16% on average per year.
SRT3 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.92% yearly.
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 52.24, the valuation of SRT3 can be described as expensive.
75.00% of the companies in the same industry are cheaper than SRT3, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.76. SRT3 is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 39.96, SRT3 can be considered very expensive at the moment.
80.00% of the companies in the same industry are cheaper than SRT3, based on the Price/Forward Earnings ratio.
SRT3 is valuated expensively when we compare the Price/Forward Earnings ratio to 22.63, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.24 | ||
| Fwd PE | 39.96 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 65.00% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as SRT3.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.27 | ||
| EV/EBITDA | 23.29 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SRT3 does not grow enough to justify the current Price/Earnings ratio.
SRT3's earnings are expected to grow with 22.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.25
PEG (5Y)N/A
EPS Next 2Y20.61%
EPS Next 3Y22.38%
5. Dividend
5.1 Amount
With a yearly dividend of 0.38%, SRT3 is not a good candidate for dividend investing.
SRT3's Dividend Yield is comparable with the industry average which is at 0.69.
Compared to an average S&P500 Dividend Yield of 2.31, SRT3's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
SRT3 pays out 37.92% of its income as dividend. This is a sustainable payout ratio.
SRT3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP37.92%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
FRA:SRT3 (10/29/2025, 5:29:48 PM)
238.2
+1.9 (+0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.84B
Revenue(TTM)3.52B
Net Income(TTM)133.70M
Analysts80
Price Target314.94 (32.22%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.8%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.91%
EPS beat(4)1
Avg EPS beat(4)-3.45%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.91%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.18%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)1.1%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.03%
PT rev (3m)-11.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0.3%
Revenue NQ rev (1m)2.88%
Revenue NQ rev (3m)2.88%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-1.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.24 | ||
| Fwd PE | 39.96 | ||
| P/S | 5.07 | ||
| P/FCF | 37.27 | ||
| P/OCF | 20.4 | ||
| P/B | 6.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.29 |
EPS(TTM)4.56
EY1.91%
EPS(NY)5.96
Fwd EY2.5%
FCF(TTM)6.39
FCFY2.68%
OCF(TTM)11.68
OCFY4.9%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)2.25
PEG (5Y)N/A
Graham Number60.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.39% | ||
| ROE | 5.01% | ||
| ROCE | 6.33% | ||
| ROIC | 4.71% | ||
| ROICexc | 4.98% | ||
| ROICexgc | 17.77% | ||
| OM | 14.06% | ||
| PM (TTM) | 3.8% | ||
| GM | 46.48% | ||
| FCFM | 13.61% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.28 | ||
| Debt/FCF | 8.92 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 92.32% | ||
| Cap/Sales | 11.25% | ||
| Interest Coverage | 2.65 | ||
| Cash Conversion | 94.72% | ||
| Profit Quality | 357.97% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.49 | ||
| Altman-Z | 2.4 |
F-Score7
WACC7.64%
ROIC/WACC0.62
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.23%
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.54%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year99.69%
EBIT Next 3Y38.21%
EBIT Next 5Y26.49%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%
SARTORIUS AG-VORZUG / SRT3.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.
What is the valuation status for SRT3 stock?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS AG-VORZUG?
SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.
Can you provide the PE and PB ratios for SRT3 stock?
The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 52.24 and the Price/Book (PB) ratio is 6.68.
What is the expected EPS growth for SARTORIUS AG-VORZUG (SRT3.DE) stock?
The Earnings per Share (EPS) of SARTORIUS AG-VORZUG (SRT3.DE) is expected to grow by 23.27% in the next year.